Skip to main content
PROK logo

ProKidney Corp.

PROKNASDAQHealthcareBiotechnology

$1.52Today:- (-)1Y −55.17%

As of Oct 28, 2026 close

Market cap
$283.57M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$1.30$3.48
Volume (live)
-
Avg. volume (3M)
1.49M

ProKidney (PROK) Cash Flow Statement

In fiscal 2025 (fiscal year ended Dec 31, 2025), ProKidney used $120.12M of cash in operating activities and spent $15.20M on capital expenditures. That left free cash flow of −$135.31M.

ProKidney Cash Flow Statement Analysis

Values in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for ProKidney Corp. (PROK) - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Period endingDec 2025Mar 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Operating Activities
Net Income-151.61-163.34-163.34-135.45-148.14-55.15-26.75-0.08
Depreciation & Amortization6.585.435.433.853.041.980.960.00
Stock Based Compensation25.3429.3729.3730.8574.470.700.730.00
Change in Working Capital1.283.963.9616.67-6.462.16-0.130.00
Change in Accounts Receivable1.32-1.07--1.380.000.000.000.00
Change in Accounts Payable-5.9211.5910.9811.640.770.010.680.00
Change in Other Working Capital1.28-6.56-0.1616.67-6.952.16-0.810.00
Other Operating Activities-1.70-1.78-0.16-6.000.000.000.000.00
Net Cash from Operating Activities-120.12-126.35-126.35-90.07-77.09-50.30-25.18-0.08
Investing Activities
Capital Expenditures-15.20-29.51-29.51-34.20-1.85-5.19-5.460.00
Acquisitions18.220.00-0.000.110.000.000.00
Purchases of Investments-217.08-324.02-324.02-471.600.000.000.000.00
Sales/Maturities of Investments318.02373.95373.95175.820.000.000.000.00
Net Cash from Investing Activities103.9720.4120.41-329.98-1.74-5.19-5.460.00
Financing Activities
Debt Repayment-0.03-0.05-0.05-0.05-35.03-0.03-0.010.00
Common Stock Issued25.60144.32144.320.006.0571.5020.000.00
Common Stock Repurchased0.000.00--9.500.000.000.000.00
Other Financing Activities-0.030.14-0.05-0.05548.550.0020.000.02
Net Cash from Financing Activities25.57144.41144.41-9.55548.5271.4719.990.02
Summary
Effect of Forex Changes on Cash0.000.00-0.000.000.000.000.08
Net Change in Cash9.4238.4738.47-429.60469.6915.98-10.650.02
Cash at Beginning of Period99.1260.6560.65490.2520.564.5815.230.00
Cash at End of Period108.5499.1299.1260.65490.2520.564.580.02
Free Cash Flow-135.31-155.86-155.86-124.27-78.94-55.49-30.64-0.08
Supplemental Disclosures
Income Taxes Paid--0.072.861.950.07--

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About ProKidney Cash Flow

What is ProKidney's free cash flow?

ProKidney had negative free cash flow of $135.31M in fiscal 2025 (fiscal year ended Dec 31, 2025), operating cash flow of −$120.12M minus $15.20M of capital expenditures.

How much does ProKidney spend on capital expenditures?

ProKidney spent $15.20M on capital expenditures in fiscal 2025, compared with $29.51M a year earlier.

Does ProKidney pay dividends or buy back shares?

ProKidney's cash flow statement for fiscal 2025 shows no dividend payments or share repurchases.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition